Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab
Radioimmunotherapy, targeting the CD20 antigen, in B-cell lymphoma has clearly demonstrated efficacy and tolerability over the preceding 15 years. As a result, two products are available with Food and Drug Administration approval for marketing – Y90 ibritumomab tiuxetan and I131 tositumomab, given as the Zevalin and Bexxar therapeutic regimens, respectively. Both demonstrate high-response rates and durability of remission in the relapsed/refractory disease setting. Data are emerging regarding their utility as initial therapy, and furthermore, they are been investigated for use sequentially with chemotherapy, and in the myeloablative setting. As yet however, how to best use these agents in the clinical disease course remains uncertain
radioimmunotherapy, non-Hodgkin's lymphoma, tositumomab, ibritumomab, monoclonal antibodies, CD20
3614-3628
Davies, A.J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
28 May 2007
Davies, A.J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Davies, A.J.
(2007)
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.
Oncogene, 26 (25), .
(doi:10.1038/sj.onc.1210378).
Abstract
Radioimmunotherapy, targeting the CD20 antigen, in B-cell lymphoma has clearly demonstrated efficacy and tolerability over the preceding 15 years. As a result, two products are available with Food and Drug Administration approval for marketing – Y90 ibritumomab tiuxetan and I131 tositumomab, given as the Zevalin and Bexxar therapeutic regimens, respectively. Both demonstrate high-response rates and durability of remission in the relapsed/refractory disease setting. Data are emerging regarding their utility as initial therapy, and furthermore, they are been investigated for use sequentially with chemotherapy, and in the myeloablative setting. As yet however, how to best use these agents in the clinical disease course remains uncertain
This record has no associated files available for download.
More information
Published date: 28 May 2007
Keywords:
radioimmunotherapy, non-Hodgkin's lymphoma, tositumomab, ibritumomab, monoclonal antibodies, CD20
Identifiers
Local EPrints ID: 73324
URI: http://eprints.soton.ac.uk/id/eprint/73324
ISSN: 0950-9232
PURE UUID: 76e4519d-f836-4dca-8e2b-4ca3dbb34b1f
Catalogue record
Date deposited: 05 Mar 2010
Last modified: 14 Mar 2024 02:54
Export record
Altmetrics
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
